Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2019

View Archived Issues

Preclinical characterization of the novel covalent Inhibitor of CDK7, SY-1365

Checkpoint blockade protects from homeostatic inhibition and amplifies antitumor T-cell responses

POU3F3 disruptions linked to neurodevelopmental disorder

Panitumumab-IRDye800 in phase II for metastatic lymph node identification in HNSCC

First preclinical data presented on miR-132 inhibitor CDR132L in heart failure model

Alcohol consumption is deceased with FGFR1 inhibition in rodents

Lower affinity means lower affinity, but higher persistence, for CAR T cells

Eicosis' soluble epoxide hydrolase inhibitor EC-5026 to enter the clinic

UCn2 gene transfer improves diabetes-related left-ventricular dysfunction in mice

KBP Biosciences patents new bacterial LpxC inhibitors

HIV rebound shows diverse sources, identical virus

Daiichi Sankyo presents new analgesics

TREM2 correlates with slow decline in AD

Crinetics Pharmaceuticals identifies somatostatin SST5 receptor agonists

Eli Lilly and Company describes PDE1 inhibitors

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

ObsEva reports mechanism-of-action data on oxytocin receptor antagonist nolasiban

FDA approves Kuros' IND for phase IIa trial of KUR-113 for spinal fusion

Twinrab approved in India for rabies

Grunenthal and UniQuest establish neuropathic pain collaboration

Boehringer Ingelheim to advance BI-456906 into phase II for obesity and diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.